GlaxoSmithKline enters 5 year agreement with NeuroSearch  

The medical giant takes an 8% stake in the Danish biotech company and acquires sales rights to a pipeline drug

Anglo-American medical giant GlaxoSmithKline has entered a 5 year research and development agreement with the Danish biotech company NeuroSearch. In the next 5 years NeuroSearch is guaranteed payments of DKK 610 million (USD 104 million) which will finance the company’s research costs for 2004. GlaxoSmithKline has also acquired sales rights to a new drug – called ns2359 – for the treatment of hyperkinetic children.


If NeuroSearch reaches the expected milestones in developing ns2359 it will receive a further DKK 733 million (USD 125 million) in payments on top of the DKK 610 million. As a part of the agreement GlaxoSmithKline becomes a shareholder in NeuroSearch with 8% ownership.


NeuroSearch is a biopharmaceutical company with compounds in clinical development and a portfolio of drug discovery programmes primarily focused on the area of CNS diseases. The news is reported by national daily newspaper Jyllands-Posten.


Link > NeuroSearch

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×